Last reviewed · How we verify

Enoxaparine infusion — Competitive Intelligence Brief

Enoxaparine infusion (Enoxaparine infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low-molecular-weight heparin (LMWH). Area: Cardiovascular.

phase 3 Low-molecular-weight heparin (LMWH) Coagulation factors Xa and IIa (via antithrombin III enhancement) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Enoxaparine infusion (Enoxaparine infusion) — GlaxoSmithKline. Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Enoxaparine infusion TARGET Enoxaparine infusion GlaxoSmithKline phase 3 Low-molecular-weight heparin (LMWH) Coagulation factors Xa and IIa (via antithrombin III enhancement)
Dosing of enoxaparin for VTE prophylaxis Dosing of enoxaparin for VTE prophylaxis Intermountain Health Care, Inc. marketed Low-molecular-weight heparin (LMWH) Factor Xa and Factor IIa (via antithrombin III enhancement)
enoxaparin/tinzaparin/dalteparin enoxaparin/tinzaparin/dalteparin Helsinki University Central Hospital marketed Low-molecular-weight heparin (LMWH) Antithrombin III (indirect); Factor Xa and Factor IIa
Intermediate dose tinzaparin Intermediate dose tinzaparin Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) marketed Low-molecular-weight heparin (LMWH) Antithrombin III (indirect target); Coagulation factors Xa and IIa
Enoxaparin (High-dose Group) Enoxaparin (High-dose Group) Peking Union Medical College Hospital marketed Low-molecular-weight heparin (LMWH) Antithrombin III (enhancer); Coagulation factors Xa and IIa (indirect targets)
Sodium Enoxaparine Sodium Enoxaparine Biocad marketed Low-molecular-weight heparin (LMWH) Factor Xa and Factor IIa (via antithrombin III enhancement)
Low dose nadroparin Low dose nadroparin Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) marketed Low-molecular-weight heparin (LMWH) Factor Xa, Thrombin (Factor IIa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low-molecular-weight heparin (LMWH) class)

  1. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 7 drugs in this class
  2. University of Melbourne · 3 drugs in this class
  3. French Cardiology Society · 2 drugs in this class
  4. Ottawa Hospital Research Institute · 2 drugs in this class
  5. McMaster University · 2 drugs in this class
  6. Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
  7. GlaxoSmithKline · 1 drug in this class
  8. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
  9. Cristália Produtos Químicos Farmacêuticos Ltda. · 1 drug in this class
  10. Helsinki University Central Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Enoxaparine infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/enoxaparine-infusion. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: